U.S. Markets closed

XOMA Corporation (XOMA)


NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
6.66-0.08 (-1.19%)
At close: 4:00PM EDT

6.66 0.00 (0.00%)
After hours: 4:06PM EDT

People also watch
CTICVICLIMMUVVUSAGEN
  • The scenarios are quite interesting at current levels for XOMA. have you guys heard of awesom-eSTOCKS. i started receiving their allerts and so far i am happy.
  • up
    Imageclterryart
  • appears history is going to repeat itself!
  • I also received an alert for $XOMA from http://thesubwaytrader.com/?s=XOMA , any ideas? Day trading investing. There is a tide in the affairs of men which

    The Subway Trader: Trading Stocks and Making Money
    Stock alerts from the The Subway Trader. Stock trading, making money and always looking for the next big money maker.
    thesubwaytrader.com
  • still a piece of garbage no matter what the price.
  • AXSM (MC $85 M)(Cash $50 M) 5x BIG Phase 3 in various indications targeting large Markets with first interim results in 2H 2017 = 2000%+ POTENTIAL..UNKNOWN LOW FLOAT GEM !!!

    Undiscovered and massive undervalued Biotech Stock with lots of Big News on the way.This Stock is brutally undervalued with a Market cap of just $85 million and $50 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) more than 50% of O/S is owned by Insider and Institutions which is a great sign .

    This undiscovered stock could be the next 10 bagger gem if just one of their 5 ongoing Phase 3 programs is successful .GL

    Axsome (AXSM)

    Market-Cap: $85 Million
    Cash: $50.6 Million(cash runway into the first quarter of 2019.)
    Price:$3.70

    Shares Out: 23 Million

    Anticipated Near-Term Clinical Milestones

    Clinical Trial Initiations: -- Phase 2/3 clinical trial of AXS-05 in AD agitation (2Q 2017)

    Clinical Trial Readouts:

    -- Phase 3 COAST-1 trial of AXS-02 in knee OA associated with BMLs, interim analysis (3Q 2017)

    -- Phase 3 CREATE-1 trial of AXS-02 in CRPS, interim efficacy analysis (4Q 2017)

    -- Phase 3 STRIDE-1 trial of AXS-05 in TRD, top-line data (1Q 2018)

    New Presentation April
    http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NjY0Mzk1fENoaWxkSUQ9MzcyMTk4fFR5cGU9MQ==&t=1

    HUGE Pipeline targeting Billion Dollar Markets:
    http://axsome.com/wp-content/uploads/2016/11/Axsome_Dec2016_Pipeline.png

    AXS-05 Treatment Resistant Depression in Phase 3 -(Only 1 approved drug for TRD = unmet medical need. 3M patients in the U.S.)

    AXS-05 Agitation in Alzheimer’s Disease in Phase 2/3 -(No approved medication = unmet medical need. 2M patients in the U.S.)

    AXS-02 Complex Regional Pain Syndrome (CRPS) in Phase 3 (Orphan+Fast Track Status) -(No approved drug = high unmet need. 80,000 new cases per year in the U.S.)

    AXS-02 Knee Osteoarthritis (OA) with Bone Marrow Lesions (BMLs) in Phase 3 (SPA & Fast Track) -(7M patients in the U.S.)

    AXS-02 Chronic Low Back Pain(CLBP) with Modic Changes (MCs) in Phase 3 -(1.6M patients in the U.S.)

    Major Shareholders

    Herriott Tabuteau, MD 7 351 729 38,4%
    Fidelity Management & Research Co. 2 361 625 12,3%
    JPMorgan Asset Management (UK) Ltd. 1 432 456 7,48%
    Mark Coleman, MD 647 998 3,38%
    BlackRock Fund Advisors 426 837 2,23%
    Stifel Trust Co., NA 415 279 2,17%
    The Vanguard Group, Inc. 272 189 1,42%
    Lombard Odier Asset Management (USA) Corp. 250 000 1,31%
    JPMorgan Investment Management, Inc. 156 625 0,82%
    SSgA Funds Management, Inc. 134 688 0,70%

  • Here's a cut/paste fron yesterdays SEC filing. Choke on this shareholders. They've been fleecing generations of fools and enriching themselves in the process.
    Summary Compensation Table
    The following table sets forth certain summary information for the years indicated concerning the compensation earned by the Company’s current and former Chief Executive Officer, Chief Financial Officer, and two individuals who would have been one of our three most highly compensated executive officers except for the fact that they were not serving as executive officers as of December 31, 2016.

    Name and Principal Position

    Year Salary
    ($) Stock
    Awards
    ($)(1) Option
    Awards
    ($)(2) Non-Equity
    Incentive Plan
    Compensation
    ($)(3) All other
    Compensation
    ($)(4) Total
    ($)
    James Neal

    2016 $ 400,000 $ 189,977 $ 428,060 $ 90,118 $ 16,895 $ 1,125,050
    (Chief Executive Officer)

    2015 $ 354,165 $ 201,075 $ 187,717 $ 132,384 $ 16,895 $ 892,236
    John Varian

    2016 $ 588,290 $ 413,295 $ 0 $ 133,885 $ 741,298 $ 1,876,768
    (Former CEO, Chairman of

    2015 $ 586,572 $ 739,956 $ 690,799 $ 275,689 $ 14,967 $ 2,307,983
    the Board)

    2014 $ 569,487 $ 1,080,747 $ 1,110,786 $ 264,812 $ 14,080 $ 3,039,912
    Tom Burns

    2016 $ 322,973 $ 82,842 $ 149,821 $ 60,364 $ 9,590 $ 625,590
    (Senior Vice President,

    2015 $ 274,749 $ 85,256 $ 91,454 $ 87,380 $ 9,381 $ 548,220
    Finance and Chief Financial

    Officer)

    Paul D. Rubin, M.D.

    2016 $ 382,776 $ 151,346 $ 0 $ 97,271 $ 4,713 $ 636,106
    (Former Senior Vice President

    2015 $ 423,299 $ 248,567 $ 225,027 $ 159,161 $ 14,386 $ 1,070,440
    Research and Development and

    2014 $ 410,970 $ 612,946 $ 629,983 $ 146,125 $ 11,406 $ 1,811,430
    Chief Medical Officer)

    Patrick J. Scannon, M.D., Ph.D.

    2016 $ 250,999 $ 106,834 $ 0 $ 50,210 $ 228,240 $ 636,283
    (Former Executive Vice

    2015 $ 250,262 $ 149,140 $ 135,016 $ 82,337 $ 18,934 $ 635,689
    President and Chief Scientific

    2014 $ 250,262 $ 387,122 $ 397,887 $ 78,833 $ 18,434 $ 1,132,535
    Officer)
  • Lets see some volume
  • Anne, you may take your junk to your friends and leave us alone.
    This board is for serious posters, not for paid advertisers....
  • If you can dream it, you can do it. http://dataunion.tistory.com/3697

    XOMA Corp NASDAQ : XOMA Correlation Histogram
    X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks May-2016 1,000 Day Parameter 2,830 NASDAQ Stocks Price Analysis This stock mode of correlation coefficient is 0 In other words, the correlation coefficient of the other stocks
    dataunion.tistory.com
  • Received an alert this am about $XOMA from http://yugestocks.com/?s=XOMA, you may want to take a look. Terman's law: there is no direct relationship between the quality of an educational program and its cost. Trading stocks making money.

    Yuge Stocks: Trading Stocks and Making Money
    Stock alerts from the Yuge Stocks. Stock trading, making money and always looking for the next big money maker.
    yugestocks.com
  • My whopping 100 shares are going up. Thanks for the R/S COMA
  • Perhaps a short-term pull back is more likely before the next rally on XOMA? Not sure how aawesomestocks finds all these incredible trade ideas but im happy.
  • I new I should have waited a bit longer...the news is just the beginning for XOMA.

    Looking for a good entry again.
  • I have no faith or trust in XOMA, they have stuck it to the investors to many times and a reverse split like the last was uncalled for. I will guess that the pump of lately is false just like always.
  • Looks like they have $ for the time being.
    Is there a FDA announcement ready to hit the wires ?
  • Is the World coming to an end? Why is XOMA moving up? Just because they paid off some of their debts?
  • I ask every investor in xoma to check out http://www.cnbc.com/pre-markets/, select xoma under " search quotes....".
    You'll find a slide presented this morning. Shows the HUGE potential for their products in the pipeline ( $$ ).
    The new guy in the B.of D. brought in $25 mill. He'll speed up the sale of the company to be able to recover ( and make some ) of his investment.
    After all, things look good to me.
    All we need is some patience and accumulate when others are scared.

    Pre-Markets
    Pre-Market Data, Stock Market Quotes, Fair Value, Futures, Volatility Index,World Markets Information
    www.cnbc.com
  • Announcing the cc only 2 days in advance points to some BIG news ( " ...XOMA’s new strategic direction and initiatives " ).. This is right after a prominent VC person joins the board. Guess there is a 80-90% chance the company will be sold or a major strategic partner was found.
    We'll see.